SCHEMBL29680342

SCHEMBL29680342

Cc1cc2c(cnn2C2CCCCO2)c(-c2ncc3c(OCC(F)(F)F)nc(OC[C@@]45CCCN4C[C@H](F)C5)nc3c2F)c1C

nearest known ligand 0.52

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KRAS P01116 20/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30922455 0.94 KRAS (0.57) KRAS
SCHEMBL30706604 0.93 KRAS (0.52) KRAS
SCHEMBL25337110 0.92 KRAS (0.46) KRAS
SCHEMBL30922417 0.92 KRAS (0.47) KRAS
SCHEMBL25335841 0.91 KRAS (0.46) KRAS
SCHEMBL25334846 0.91 KRAS (0.51) KRAS
SCHEMBL30539099 0.91 KRAS (0.51) KRAS
SCHEMBL31029499 0.90 KRAS (0.50) KRAS
SCHEMBL30706701 0.89 KRAS (0.53) KRAS
SCHEMBL30922823 0.89 KRAS (0.45) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540255-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 EP disclosed
WO-2023244615-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 WO disclosed
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 EP disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 WO disclosed